All In Biotech

Drug Trial Radar · NCT00883051

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine

Last checked: Nov 20, 2026Latest source record: Dec 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

512

Actual

Start

Jul 2009

Primary completion

Feb 2010

Study completion Feb 2010

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
CoLucid Pharmaceuticals
First posted
Apr 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.

Conditions

  • Migraine Disorders

Interventions

  • LasmiditanDrug

    Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Headache ResponseTime frame: 2 hours postdose

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Brussels, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Montegnée, Liege, Belgium

  • Site not named

    Hasselt, Limburg, Belgium

  • Site not named

    Leuven, Vlaams-Brabant, Belgium

  • Site not named

    Bruges, West-Vlaanderen, Belgium

  • Site not named

    Helsinki, Etelä-Suomi, Finland

  • Site not named

    Hyvinkää, Etelä-Suomi, Finland

  • Site not named

    Mikkeli, Itä-Suomen Lääni, Finland

  • Site not named

    Pori, Länsi-Suomen, Finland

  • Site not named

    Jyväskylä, Länsi-Suomi, Finland

  • Site not named

    Tampere, Länsi-Suomi, Finland

  • Site not named

    Turku, Länsi-Suomi, Finland

  • Site not named

    Paris, France

  • Site not named

    Nice, Alpes-Maritimes, France

  • Site not named

    Bordeaux, Gironde, France

  • Site not named

    Toulouse, Haute-Garonne, France

  • Site not named

    Lille, Nord, France

  • Site not named

    Rouen, Seine-Maritime, France

  • Site not named

    Berlin, Germany

  • Site not named

    Bremen, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Freiburg/Breisgau, Baden-Wurttemberg, Germany

  • Site not named

    Göppingen, Baden-Wurttemberg, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Wiesbaden, Hesse, Germany

  • Site not named

    Erkelenz, North Rhine-Westphalia, Germany

  • Site not named

    Essen, North Rhine-Westphalia, Germany

  • Site not named

    Münster, North Rhine-Westphalia, Germany

  • Site not named

    Itzehoe, Schleswig-Holstein, Germany

  • Site not named

    Seville, Andalusia, Spain

  • Site not named

    Barcelona, Catalonia, Spain

  • Site not named

    Santiago de Compostela, Galicia, Spain

  • Site not named

    Alcorcón, Madrid, Spain

  • Site not named

    Pamplona, Navarre, Spain

  • Site not named

    Oviedo, Principality of Asturias, Spain

  • Site not named

    Gandia, Valencia, Spain

  • Site not named

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.